bioAffinity Technologies (NASDAQ:BIAF) Issues Quarterly Earnings Results

bioAffinity Technologies (NASDAQ:BIAF) released its earnings results on Monday. The company reported ($0.21) EPS for the quarter, Zacks reports. bioAffinity Technologies had a negative net margin of 91.22% and a negative return on equity of 205.09%. bioAffinity Technologies updated its FY 2025 guidance to EPS.

bioAffinity Technologies Trading Down 3.0 %

Shares of BIAF traded down $0.01 during trading hours on Monday, reaching $0.25. 285,815 shares of the company traded hands, compared to its average volume of 162,397. The company has a current ratio of 1.02, a quick ratio of 1.01 and a debt-to-equity ratio of 0.18. The firm has a market cap of $3.96 million, a price-to-earnings ratio of -0.31 and a beta of 3.12. The stock’s fifty day moving average price is $0.57 and its 200 day moving average price is $1.08. bioAffinity Technologies has a 12-month low of $0.25 and a 12-month high of $3.16.

About bioAffinity Technologies

bioAffinity Technologies, Inc, a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat lung cancer and other diseases of the lung at the cellular level.